ENFORTUMAB VEDOTIN-EJFV for Transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 1,179 adverse event reports in the FDA FAERS database where ENFORTUMAB VEDOTIN-EJFV was used for Transitional cell carcinoma.
Most Reported Side Effects for ENFORTUMAB VEDOTIN-EJFV
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Rash | 560 | 15.0% | 53 | 172 |
| Malignant neoplasm progression | 410 | 11.0% | 137 | 79 |
| Neuropathy peripheral | 410 | 11.0% | 22 | 61 |
| Fatigue | 281 | 7.5% | 33 | 79 |
| Pruritus | 260 | 7.0% | 25 | 95 |
| Diarrhoea | 257 | 6.9% | 46 | 114 |
| Death | 238 | 6.4% | 238 | 46 |
| Decreased appetite | 230 | 6.2% | 34 | 95 |
| Off label use | 193 | 5.2% | 28 | 48 |
| Alopecia | 185 | 5.0% | 19 | 48 |
| Nausea | 168 | 4.5% | 18 | 79 |
| Skin disorder | 157 | 4.2% | 26 | 80 |
| Pyrexia | 156 | 4.2% | 32 | 94 |
| Hyperglycaemia | 148 | 4.0% | 30 | 77 |
| Taste disorder | 142 | 3.8% | 12 | 40 |
Other Indications for ENFORTUMAB VEDOTIN-EJFV
Product used for unknown indication (1,061)
Bladder cancer (530)
Transitional cell carcinoma metastatic (390)
Ureteric cancer (106)
Malignant neoplasm of renal pelvis (103)
Metastatic carcinoma of the bladder (96)
Bladder transitional cell carcinoma (68)
Transitional cell cancer of the renal pelvis and ureter (58)
Bladder cancer stage iv (24)
Metastases to lymph nodes (23)
Other Drugs Used for Transitional cell carcinoma
PEMBROLIZUMAB (1,951)
GEMCITABINE (825)
ATEZOLIZUMAB (788)
CISPLATIN (672)
ENFORTUMAB VEDOTIN (649)
NIVOLUMAB (595)
AVELUMAB (554)
CARBOPLATIN (493)
GEMCITABINE\GEMCITABINE (255)
PACLITAXEL (215)